Cambrex Corporation completed construction in April of 2019 on a $24 million facility for the manufacture of highly potent active pharmaceutical ingredients (HPAPIs) in Charles City, Iowa. The 6,000-sf project houses four reactors with capacities ranging from 200 to 1,000 gallons to accommodate batches from 50 to 300 kilograms. An existing small scale manufacturing area has also been reconfigured.
The International Society for Pharmaceutical Engineering has announced the winners of the 2019 Facility of the Year Awards.
ONE Life Sciences is planning to construct the £40 million Bio-Therapeutics Hub for Innovation in Aberdeen in the United Kingdom. Located on the Foresterhill Health Campus, the 69,000-sf facility will provide business incubation space, leasable labs and offices for established companies, collaboration areas, conference rooms, and venues for events and colloquia.
The University of Toronto is planning to create Canada's largest university-based innovation node with the construction of the 750,000-sf Schwartz Reisman Innovation Centre. Funded in part by a $100 million donation, the interdisciplinary center will feature vertical gardens, soaring atria, and integrated collaboration areas, as well as offering leasable space for startup companies.
Merck opened the first M Lab™ Collaboration Center in Europe in March of 2019. Located in Molsheim, France, the facility provides biopharmaceutical customers with a shared, exploratory environment where they can work with Merck scientists and engineers to accelerate the manufacture of new therapies. The 43,000-sf facility offers advanced simulation technologies in a non-GMP environment for end-to-end process development from pre-clinical through full-scale production.
The University of Groningen will begin construction in summer of 2019 on the 690,000-sf Feringa Building in the Netherlands. The $285 million facility will provide labs, cleanrooms, lecture halls, classrooms, and offices to support science and engineering programs. Specialized laboratories, located entirely on the north face of the building to mitigate weather conditions, will accommodate research in materials science, nanotechnology, chemical engineering, and astronomy.
Cellectis entered into a lease agreement in March of 2019 to build the Innovative Manufacturing Plant for Allogeneic Cellular Therapies (IMPACT) in Raleigh, N.C. Designed by Laporte Euro, the facility will produce immunotherapies based on gene-edited allogeneic CAR T-cells (UCART). Colliers International assisted in the real estate transaction. In addition, Cellectis is building a 14,000-sf manufacturing facility in Paris.
Amicus Therapeutics is creating the Global Research and Gene Therapy Center of Excellence in Philadelphia. The 75,000-sf facility will provide collaborative laboratories and offices for the discovery and development of treatments for rare metabolic diseases. Accommodating up to 200 employees, the center will serve as the headquarters for the global Amicus science organization and the gene therapy division’s leadership team. Occupancy is expected in the second half of 2019.
Akouos, a genetic medicine company, has leased 37,500 sf in Boston for its research headquarters. The facility is located in a two-story, 150,000-sf building at 645 Summer Street and will support the discovery and commercialization of therapies for hearing disorders. The project was developed by Pappas Enterprises and renovated by Tocci Building Corporation. The sustainably designed structure has attained LEED Silver certification.
Rosalind Franklin University is building the $50 million Innovation and Research Park in North Chicago, Ill. The four-story, 100,000-sf facility will provide leading-edge research labs, business incubator space, meeting rooms, and common areas. The project will promote collaboration among faculty, industry scientists, and biotech entrepreneurs in order to accelerate the discovery and commercialization of new medical treatments and therapeutics.
Autolus Therapeutics has signed a long-term, full-building lease with Alexandria Real Estate Equities for the construction and development of a build-to-suit facility in Rockville, Md. Located in the Shady Grove Life Sciences Center, the 85,000-sf project will accommodate the company's U.S. headquarters and a commercial-scale manufacturing center for cell therapies. Occupancy is expected in 2021.
Catalent is initiating an expansion of its biologics manufacturing operations. The global biotechnology company will construct a 60,000-sf facility on its existing campus in Madison, Wis. The project is slated for completion by 2021 and represents an investment of $100 million over the next three years. Catalent will also invest $100 million to increase its manufacturing capacity in Bloomington, Ind.
Global life science company Promega is constructing a $190 million research and development center on its existing campus in Fitchburg, Wis. Offering laboratories with sophisticated infrastructure to support the creation of innovative bioscience products and technologies, the three-story, 270,000-sf facility will enable the consolidation of operations currently located in three separate buildings. Ground was broken on the project in July of 2018 and occupancy is expected in fall of 2020.
Brammer Bio is developing two gene therapy manufacturing facilities in Massachusetts. The company will build out 35,000 sf in an existing 50,000-sf structure in Lexington to create a cGMP manufacturing and quality control operations center. Additionally, Brammer will renovate 8,000 sf in its 66,000-sf commercial cGMP plant in Cambridge to create new production suites to support manufacturing capacity expansion. DPS Group is providing architectural and engineering services for both projects, which are slated for completion in mid-2019.
16 Tech Community Corporation broke ground in December of 2018 on the $30 million Advanced Research and Innovation Facility in Indianapolis. The Indiana Biosciences Research Institute will lease over 67,000 sf on the first three floors of the building to accommodate researchers engaged in the study of diabetes, nutrition, and metabolics. Indiana University School of Medicine will locate the Center for Regenerative Medicine's molecular therapeutics program in 12,000 sf of the facility, which will also house the Central Indiana Corporate Partnership.
